We are coming into the fall and the third quarter, after a surprisingly solid push from the markets over the summer. Analysts may say it isn’t fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no “sell in May and go away” and even weak economic data and earnings seem immaterial at this point.

The bull market is now over seven years old. Still, the Dow, S&P 500 and Nasdaq still are flirting with all-time highs. Many investors are perplexed, and they also are looking for other ideas for how to make money ahead.

24/7 Wall St. reviews dozens of analyst research reports every day. This ends up being hundreds of analyst reports each week. Our goal is to find new investing and trading ideas for our readers.

What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are saying they can fill the prescription.

Sophiris Bio Inc. (NASDAQ: SPHS) was recently started with an Overweight rating and a $7 price target at Piper Jaffray. Shares closed Friday at $3.11, with a consensus analyst price target of $7.83 and a 52-week trading range of $2.96 to $3.29.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was raised to a Buy rating from Hold, and the price target was increased to $12 from $9, at Jefferies. The firm said its call is based on its future revenue opportunity in multiple myeloma. Its shares most recently closed at $10.62, with a consensus price target of $16.30 and a 52-week range of $4.83 to $19.41.

Nivalis Therapeutics Inc. (NASDAQ: NVLS) was recently named as one of Stifel’s three stocks that could double. Shares closed at $6.38. The consensus price target is $25.00, and the 52-week range is $5.89 to $6.60.

Array BioPharma Inc. (NASDAQ: ARRY) was reiterated as a Buy and the price target was raised to $7 from $6 at Jefferies in late August. The stock was last trading at $3.50, with a consensus price target of $8.00 and a 52-week range of $2.38 to $5.98.

Recro Pharma Inc. (NASDAQ: REPH) was started a Buy at Janney late in August as well. It was also given a $21 price target, which was practically double recent closing prices. Shares ended Friday at $9.46, with a consensus price target of $23.50 and a 52-week range of $5.59 to $17.25.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.